Alphamab Oncology’s Controlling Shareholder to Sell 1.51% Stake

Alphamab Oncology ( (HK:9966) ) has provided an update.

Alphamab Oncology announced that its controlling shareholder, Rubymab Ltd., has entered into a share placing agreement with Morgan Stanley & Co. International plc to sell 14,600,000 existing shares, representing approximately 1.51% of the company’s total issued share capital. This transaction is expected to slightly reduce Rubymab Ltd.’s stake in the company from 32.5% to 31.0%, potentially impacting the company’s shareholder structure and market perception.

The most recent analyst rating on (HK:9966) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.

More about Alphamab Oncology

Alphamab Oncology is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company operates in the oncology industry and is known for its research and development of biologics and antibody therapies targeting various cancer types.

Average Trading Volume: 4,443,260

Technical Sentiment Signal: Hold

Current Market Cap: HK$8.62B

For detailed information about 9966 stock, go to TipRanks’ Stock Analysis page.